• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cingulate moves controlled-release ADHD drug to human testing

June 2, 2017 By Sarah Faulkner

Cingulate TherapeuticsCingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by its development partner, Bio-Images Drug Delivery.

The trial enrolled healthy volunteers to evaluate the pharmacokinetic behavior of CTX-1301, including the body’s absorption, distribution, metabolism and excretion of the drug. The drug uses multi-core, timed-release technology to last the entire active day and minimize the patient’s “crashing” feeling in the afternoon, according to the company.

The controlled-release OralogiK technology was developed by BDD.

Cingulate said it expects to report findings from the trial in the 3rd quarter of this year.

“The breakthrough multi-core technology employed in CTX-1301 and CTX-1302 combines layers of immediate, delayed and sustained release medication in a single tablet intended to deliver the appropriate dose and at the right time when ADHD patients need it,” chairman & CEO Shane Schaffer said in prepare remarks. “This study intends to demonstrate the ability of our technology to achieve the target product profiles in advance of filing separate IND applications with the U.S. Food & Drug Administration by the end of this year.”

“We are delighted to be working with Cingulate Therapeutics to develop this exciting new product which is now undergoing clinical evaluation using our pharmaco-scintigraphic capabilities,” Carol Thomson, CEO of BDD, added. “The OralogiK technology is uniquely positioned to deliver the tri-phasic release profile required of the CTX-1301 and CTX-1302 products.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: bioimagesdrugdelivery, cingulatetherapeutics

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS